Described are methods, devices, and systems for a novel, inexpensive, easy to use therapy for providing treatment to the brain. Described are methods and devices to provide treatment to the brain that involves no medication. Methods and devices described herein use alternating magnetic fields to provide treatment to the brain.

A typing data analysis system may be used to accurately detect early onset of CNS diseases and psychiatric disorders based on typing data. The typing data analysis system may use distance based data analytics techniques to diagnose CNS diseases and psychiatric disorders with high accuracy. The distance based data analytics techniques may include a distance analysis that determines the distance between two or more sets of inconsistency measures that are associated with a particular individual, disease, or disorder. The distance between inconsistency measures for two or more diseases/disorders may be used to better differentiate between each disease/disorder. The distance between the inconsistency measures for an individual and a disease/disorder may help more accurately screen the individual for the disease/disorder.

Provided are systems, methods, and kits for multifunctional smell assessment. The kits may comprise a first surface adhered by a first releasable adhesive comprising an odorous volatile compound; and the system for registering if the odorous volatile compound is detected by a user. The system or method may comprise queries for obtaining a first input on whether the user detects and identifies the odorous volatile compound, and an intensity by which the odor is perceived.

Methods for preventing or treating motor-related neurological conditions include using ocular light therapy in connection with a conventional therapy for a motor-related neurological condition, such as a drug regimen, to adjust levels of melatonin and/or dopamine in the body of a subject. The ocular light therapy may include elevated levels of blue-green light or green light (e.g., light within a wavelength range of 460 nm to 570 nm, 490 nm to 570 nm, about 520 nm to 570 nm, etc.). The ocular light therapy may also include reduced levels of amber, orange and/or red light. Methods for diagnosing motor-related neurological conditions include use of ocular light therapy to cause a subject to temporarily exhibit one or more symptoms of any motor-related neurological condition to which the subject is predisposed, or which the subject may already be experiencing. A temporary increase in such symptoms may be effected by ocular administration of light including increased amounts of amber, orange and/or red light.

Currently, assessing the severity and progression of symptoms in a subject diagnosed with a muscular disability, in particular SMA involves in-clinic monitoring and testing of the subject every 6 to 12 months. However, monitoring and testing a subject more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the subject. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the subject outside of a clinic environment as described herein provides advantages in cost, ease of monitoring and convenience to the subject. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing of the motor function of a subject having a muscular disability, in particular SMA by active testing of the subject.

Currently, assessing the severity and progression of symptoms in a subject diagnosed with a muscular disability, in particular SMA involves in-clinic monitoring and testing of the subject every 6 to 12 months. However, monitoring and testing a subject more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the subject. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the subject outside of a clinic environment as described herein provides advantages in cost, ease of monitoring and convenience to the subject. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing of the axial motor function of a subject having a muscular disability, in particular SMA by active testing of the subject.

Currently, assessing the severity and progression of symptoms in a subject diagnosed with a muscular disability, in particular SMA involves in-clinic monitoring and testing of the subject every 6 to 12 months. However, monitoring and testing a subject more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the subject. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the subject outside of a clinic environment as described herein provides advantages in cost, ease of monitoring and convenience to the subject. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing of the distal motor function of a subject having a muscular disability, in particular SMA by active testing of the subj ect.

Currently, assessing the severity and progression of symptoms in a subject diagnosed with a muscular disability, in particular SMA involves in-clinic monitoring and testing of the subject every 6 to 12 months. However, monitoring and testing a subject more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the subject. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the subject outside of a clinic environment as described herein provides advantages in cost, ease of monitoring and convenience to the subject. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing of the distal hypotonia of a subject having a muscular disability, in particular SMA by active testing of the subject.

The present invention discloses indicator fluids, reference indicator fluid, and usage thereof, and systems and methods for assessing movement of molecular substances within, to or from a cerebrospinal fluid, brain or spinal cord compartment of a human cranio-spinal cavity. Indicator fluid moving from the cerebrospinal fluid compartment enables measurements of levels of indicator fluid in blood or urine and assessment of the cranio-spinal cavity's ability to remove molecular substances. The indicator fluids may be contrast agents used for imaging, such as by computed tomography imaging, and magnetic resonance imaging, or imaging utilizing radioactive substances by positron emission tomography, single-photon emission computed tomography or scintigraphy. Using these imaging modalities, the invention describes indicator fluids, systems and methods enabling assessment of movement of substances within, to or from a cerebrospinal fluid, brain or spinal cord compartment of a cranio-spinal cavity, and from the human cranio-spinal cavity to lymphatic pathways or kidneys.

A vehicle anti-vibration device includes a vibration sensor programmed to detect vibrations and output a vibration signal representing the vibrations detected. The device further includes a motor that vibrates in accordance with a vibration dampening signal, a communication interface programmed to wirelessly transmit the vibration signal to a remote device, and a processor programmed to process the vibration signal and generate the vibration dampening signal to dampen the vibrations detected.